Aegon downgraded to Neutral at UBS on limited upside potential

Investing.com -- UBS downgraded Aegon to Neutral, saying the stock’s risk-reward has become more balanced ahead of the insurer’s capital markets day (CMD) on Dec. 10.

The bank lifted its price target slightly to €7.3 from €7.2 but said its updated sum-of-the-parts (SOTP) work shows the shares are “fairly priced” with limited room for upside.

Analysts led by Nasib Ahmed expect management to outline a 2027 (FY27) free cash flow (FCF) target of about €0.9 billion, which would sit modestly below consensus.

UBS also sees a potential dividend target of 0.45 euros, slightly under market expectations.

Aegon shares have outperformed U.S. life insurers over the past year but lagged the broader European sector. UBS argues that the company’s valuation already reflects its business mix and execution risks, particularly around its U.S. operations, which account for roughly two-thirds of group earnings.

Its refreshed valuation puts Aegon’s overall SOTP range at €7 to €9.8 per share, with the base case toward the bottom end due to lingering uncertainties over unlocking value across the group.

A potential bright spot at next week’s event could come from capital returns. Analysts say Aegon has capacity for as much as €1.1 billion in share buybacks during 2026, versus its own €0.5 billion expectation.

A larger program would “be taken positively” with the bank calculating that a €1 billion repurchase would equate to 3%–4% of the company’s market capitalization.

The note also breaks down updated valuations for the group’s major components. The U.S. business, branded Transamerica, is assessed at €7.1 billion in the base case, in line with peer free-cash-flow multiples.

The U.K. arm is valued at €2.1 billion, the international division at €1.2 billion, and the asset-management unit at €1.3 billion. The holding company and other items collectively subtract €1.2 billion from the total.

While buybacks and potential disposals could support the equity story, high exposure to equity-market and credit risks offsets that upside, according to UBS.

Analysts expect Aegon to keep recurring buybacks of €300 million per year from 2027, but stresses that “execution risk and exposure to market risks remain high.”

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Exclusive: ESS Tech speeds up sodium-ion development on $1bn opportunity pipeline
• Nike slips after Evercore downgrades stock on gloomy near-term outlook